VHPB Centre for Evaluation of Vaccination (CEV) |
Executive Secretary Administrative and Scientific Secretariat |
privacy statement
|
Berlin, Germany, October 13-14, 2003
- Meeting Programme -
Monday, October 13, 2003
09.00 - 09.30
Welcome
Johannes Hallauer, Germany
Introduction of the participants
Objectives of the meeting:
Update of the epidemiological situation on viral hepatitis in Germany and the Nordic Countries;
Overview of surveillance systems for infectious diseases and adverse events following vaccination in Germany and the Nordic Countries;
Evaluation of current prevention and control measures on viral hepatitis in Germany and Nordic Countries;
Lessons learnt from the experiences in German and the Nordic Countries; successes, problems and barriers to overcome, and the way forward.
Review of the meeting programme
Epidemiology, prevention, and control of viral hepatitis in Germany and the Nordic Countries - Pre-meeting document 360 Kb (.pdf)
09.30 - 10.10
Hepatitis B epidemiology, surveillance, and prevention strategies in the Nordic Countries 146 Kb (.pdf)
Hans Blystad, Oslo, Norway
10.10 - 10.25
Epidemiology of hepatitis A in Sweden - the same old story? 298 Kb(.pdf)
Lars Rombo, Eskilstuna, Sweden
10.25 - 10.45
Coffee break
10.45 - 11.05
Problems associated with the introduction of HBsAg-positive children in day care centres 72 Kb (.pdf)
Johan Struwe, Huddinge, Sweden
11.05 - 11.25
Investigation of a cluster of nosocomial HBV infections in Sweden - obstacles and efforts 331 Kb (.pdf)
Johan Struwe, Huddinge, Sweden
11.25 - 11.55
Hepatitis A and B outbreaks among intravenous drug users in the Nordic Countries 134 Kb (.pdf)
Hans Blystad, Oslo, Norway
11.55 - 12.25
Evaluation of a hepatitis B selective vaccination programme in Norway 78 Kb (.pdf)
Hanne Nøkleby, Oslo, Norway
12.25 - 14.00
Lunch
14.00 - 14.25
Hepatitis C infection in medical settings
Sergei Viazov, Essen, Germany
14.25 - 14.50
Follow-up of iatrogenous HCV infections related to anti-Rh prophylaxis
Anne-Sophie Endres, Berlin, Germany
14.50 - 15.15
Epidemiology of hepatitis A in Germany 262 Kb (.pdf)
Katharina Alpers, Berlin, Germany
15.15 - 15.30
Coffee break
15.30 - 15.55
Epidemiology of hepatitis B in Germany 244 Kb (.pdf)
Doris Radun, Berlin, Germany
15.55 - 16.20
Molecular epidemiology of HBV mutants 2,234 Kb (.pdf)
Wolfram Gerlich, Giessen, Germany
16.20 - 16.45
Organisation of the health care system in Germany 416 Kb (.pdf)
Johannes Hallauer, Berlin, Germany
16.45 - 17.10
Federal law on communicable diseases (Infektionsschutzgesetz) - Reporting systems 258 Kb (.pdf)
Michael Kramer, Bonn, Germany
09.00 - 09.30
Development of hepatitis B prevention in Germany - the first 10 years 82 Kb (.pdf)
Wolfgang Jilg, Regensburg, Germany
09.30 - 10.00
Screening pregnant women for hepatitis B: results from two studies 88 Kb (.pdf)
Wolfgang Jilg, Regensburg, Germany
10.00 - 10.35
Groups at risk for hepatitis B infection - who should be vaccinated 121 Kb (.pdf)
Ulrich Bienzle, Berlin, Germany
10.35 - 11.00
Coffee break
Session 7 Evaluation of viral hepatitis prevention and control measures in Germany
11.00 - 11.25
Universal vaccination against hepatitis B in Germany – a paediatrician’s point of view 101 Kb (.pdf)
Uwe Büsching, Bielefeld, Germany
11.25 - 11.50
Monitoring system for adverse events following hepatitis vaccination
Johannes Hallauer, Berlin, Germany, and round-table discussion
11.50 - 12.15
School-entry monitoring of vaccination status 399 KB (.pdf)
Günter Pfaff, Stuttgart, Germany
12.15 - 12.40
Critical review of programme progress 62 Kb (.pdf)
Michael Kramer, Bonn, and Johannes Hallauer, Berlin, Germany
12.40 - 14.00
Lunch
14.00 - 15.30
Presentation of the VHPB meeting conclusions, including discussion 97 Kb (.pdf)
David FitzSimons, Geneva, Switzerland
15.30
Close of the meeting